Literature DB >> 20941832

Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells.

C Tomuleasa1, O Soritau, D Rus-Ciuca, H Ioani, S Susman, M Petrescu, T Timis, D Cernea, G Kacso, A Irimie, I S Florian.   

Abstract

PURPOSE: Brain tumors are the leading cause of cancer mortality in children and remain incurable despite advances in surgery and adjuvant therapies. The failure of malignant gliomas to respond to conventional treatment reflects the unique biology of these tumors, linked to a small population of stem-like precursors. This study describes the characteristics of stem cells isolated from glioblastoma multiforme (GM) and gives insight into the mechanism of brain tumorigenesis.
METHODS: Tumor stem-like precursors were identified from primary human GM-derived cell culture using immunocytochemistry and reverse transcription polymerase chain reaction (RT-PCR). Cells were cultured in vitro in stem cell medium supplemented with growth factors and then the capacity of the surviving stem-like precursors to form tumor spheres and to continue to proliferate after chemoradiotherapy were tested.
RESULTS: The tumor cells expressed the cellular markers CD133, CD105, CD90, Nanog, Oct 3/4, CXCR4, nestin, glial fibrillary acidic protein (GFAP), neurofilament protein (NF) and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Cells also displayed a high proliferative potential despite chemotherapy and irradiation and also had the ability to form spheroids in suspension.
CONCLUSION: High grade gliomas contain stem-like precursors, which exhibit neural stem cell properties with tumorigenicity, establishing a novel developmental paradigm in the study of brain carcinogenesis and providing a powerful tool to develop patient-tailored therapy for this devastating disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20941832

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

1.  Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Authors:  Baotran Ho; Gretchen Olson; Sheila Figel; Irwin Gelman; William G Cance; Vita M Golubovskaya
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

2.  Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.

Authors:  Dalma Deak; Cristina Pop; Alina-Andreea Zimta; Ancuta Jurj; Alexandra Ghiaur; Sergiu Pasca; Patric Teodorescu; Angela Dascalescu; Ion Antohe; Bogdan Ionescu; Catalin Constantinescu; Anca Onaciu; Raluca Munteanu; Ioana Berindan-Neagoe; Bobe Petrushev; Cristina Turcas; Sabina Iluta; Cristina Selicean; Mihnea Zdrenghea; Alina Tanase; Catalin Danaila; Anca Colita; Andrei Colita; Delia Dima; Daniel Coriu; Hermann Einsele; Ciprian Tomuleasa
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

3.  Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles.

Authors:  Anamaria Orza; Olga Soriţău; Ciprian Tomuleasa; Liliana Olenic; Adrian Florea; Ovidiu Pana; Ioan Bratu; Emoke Pall; Stefan Florian; Dan Casciano; Alexandru S Biris
Journal:  Int J Nanomedicine       Date:  2013-03-01

4.  MRI-based identification of undifferentiated cells: looking at the two faces of Janus.

Authors:  Ciprian Tomuleasa; Ioan Stefan Florian; Cristian Berce; Alexandru Irimie; Ioana Berindan-Neagoe; Andrei Cucuianu
Journal:  Int J Nanomedicine       Date:  2014-02-11

5.  In vitro Analysis of Neurospheres Derived from Glioblastoma Primary Culture: A Novel Methodology Paradigm.

Authors:  Lorena Favaro Pavon; Luciana C Marti; Tatiana Tais Sibov; Suzana M F Malheiros; Reynaldo Andre Brandt; Sergio Cavalheiro; Lionel F Gamarra
Journal:  Front Neurol       Date:  2014-01-07       Impact factor: 4.003

Review 6.  Nanopharmacology in translational hematology and oncology.

Authors:  Ciprian Tomuleasa; Cornelia Braicu; Alexandra Irimie; Lucian Craciun; Ioana Berindan-Neagoe
Journal:  Int J Nanomedicine       Date:  2014-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.